Regulatory FDA approves new high dose Spinraza regimen for SMA PharmaTimesUpdated dosing offers meaningful clinical benefitRegulatoryRare DiseaseRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Updated dosing offers meaningful clinical benefit RegulatoryRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Viridian reports positive results from elegrobart phase 3 trialNext: Ambrosia adds a megaround for obesity drugs Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
